



11-26-01

A
Bux Scy**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: Larry Wayne Oberley et al.

Title: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING ANTISENSE OLIGONUCLEOTIDES

Attorney Docket No.: 875.042US1

10872 U.S. PTO
09/993333
11/14/01**PATENT APPLICATION TRANSMITTAL****BOX PATENT APPLICATION**Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items and information (as indicated with an "X"):

Return postcard.
 Utility Patent Application under 37 CFR § 1.53(b) comprising:
 Specification (19 pgs, including claims numbered 1 through 19 and a 1 page Abstract).
 Formal Drawing(s) (11 sheets).
 Unsigned Combined Declaration and Power of Attorney (4 pgs).
Communication Under 37 CFR 1.821 (1 pg), Sequence Listing (3 pgs), and computer-readable copy of Sequence Listing (1 disk).
 Applicant claims small entity status under 37 C.F.R 1.27.

The filing fee (NOT ENCLOSED) will be calculated as follows:

	No. Filed	No. Extra	Rate	Fee
TOTAL CLAIMS	19 - 20 =	0	x 9 =	\$0.00
INDEPENDENT CLAIMS	2 - 3 =	0	x 42 =	\$0.00
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED				\$0.00
BASIC FEE				\$370.00
TOTAL				\$370.00

THE FILING FEE WILL BE PAID UPON RECEIPT OF THE NOTICE TO FILE MISSING PARTS.SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)By: ASL
Atty: Ann S. Viksnins
Reg. No. 37,748**Customer Number 21186**"Express Mail" mailing label number: EL 873858675 USDate of Deposit: November 14, 2001

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to The Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

S/N Unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Larry Wayne Oberley et al. Examiner: Unknown
Serial No.: Unknown Group Art Unit: Unknown
Filed: Herewith Docket: 875.042US1
Title: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS
USING ANTISENSE OLIGONUCLEOTIDES

COMMUNICATION UNDER 37 C.F.R. § 1.821

BOX PATENT APPLICATION

Commissioner for Patents
Washington, D.C. 20231

Sir:

A SEQUENCE LISTING, to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 through 1.825, is submitted herewith.

In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith. The contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted herewith are the same.

Respectfully submitted,

LARRY WAYNE OBERLEY ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6961

Date 14 November 2001

By *ASL*

Ann S. Viksnins
Reg. No. 37,748

"Express Mail" mailing label number: EL 873 858 675 US

Date of Deposit: November 14, 2001

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.